The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What advances in CAR T for multiple myeloma have occurred since last year's meeting?

Jan 31, 2020

During the 2nd European CAR T Cell Meeting in Sitges, ES, the Multiple Myeloma Hub was delighted to speak to Hermann Einsele from University Hospital of Würzburg, Würzburg, DE. We asked: What advances in CAR T for multiple myeloma have occurred since last year's meeting?

Hermann Einsele discusses the new developments made in CAR T cell programs for patients with multiple myeloma. He explains that even though the patient populations are mainly made up of heavily pre-treated patients at a late stage of the disease there are studies that show a high response rate to CAR T therapy.

What advances in CAR T for multiple myeloma have occurred since last year's meeting?